Failure Of Roche’s Nine-Year Alzheimer’s Prevention Study Disappointing, But No Surprise
Crenezumab Fails Again
The ambitious prevention study in people with a nearly 100% chance of developing Alzheimer’s disease has failed, and attention will now switch to trial readouts for the next generation of beta-amyloid targeting candidates.
